<p>随着亚洲市场在全球经济变动中经历波动，投资者越来越关注在该地区多样化的市场中识别机会。在这种环境下，似乎被低估的股票为那些希望利用潜在市场低效的人提供了引人注目的可能性。</p>
<h3>基于现金流的亚洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>SRE Holdings (TSE:2980)</td>
<td>¥3180.00</td>
<td>¥6197.35</td>
<td>48.7%</td>
</tr>
<tr>
<td>SILICON2 (KOSDAQ:A257720)</td>
<td>₩53700.00</td>
<td>₩105825.30</td>
<td>49.3%</td>
</tr>
<tr>
<td>Nanya Technology (TWSE:2408)</td>
<td>NT$43.95</td>
<td>NT$87.09</td>
<td>49.5%</td>
</tr>
<tr>
<td>江苏云亿电气有限公司 (SZSE:300304)</td>
<td>CN¥11.08</td>
<td>CN¥22.02</td>
<td>49.7%</td>
</tr>
<tr>
<td>Heartland Group Holdings (NZSE:HGH)</td>
<td>NZ$0.80</td>
<td>NZ$1.58</td>
<td>49.5%</td>
</tr>
<tr>
<td>广东丸美生物科技 (SHSE:603983)</td>
<td>CN¥40.73</td>
<td>CN¥79.37</td>
<td>48.7%</td>
</tr>
<tr>
<td>GEM (SZSE:002340)</td>
<td>CN¥6.54</td>
<td>CN¥13.00</td>
<td>49.7%</td>
</tr>
<tr>
<td>Finger (KOSDAQ:A163730)</td>
<td>₩13480.00</td>
<td>₩26287.84</td>
<td>48.7%</td>
</tr>
<tr>
<td>cottaLTD (TSE:3359)</td>
<td>¥442.00</td>
<td>¥868.15</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$276.50</td>
<td>NT$541.44</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们基于现金流的 282 只被低估的亚洲股票的完整列表。</p>
<p>我们将从我们的筛选结果中审查一些选项。</p>
<h2>中粮糖业控股有限公司 (SHSE:600737)</h2>
<p><strong>概述：</strong> 中粮糖业控股有限公司在中国及国际上从事糖和番茄加工，市值为 CN¥218.4 亿。</p>
<p><strong>运营：</strong> 中粮糖业控股有限公司主要通过其在国内和国际市场的糖和番茄加工活动产生收入。</p>
<p><strong>公允价值折扣估计：</strong> 40.3%</p>
<p>中粮糖业控股有限公司的交易价格为 CN¥10.21，显著低于其估计的公允价值 CN¥17.11，表明基于折现现金流分析的潜在低估。预计该公司的收益将以每年 36.89% 的速度显著增长，超过中国市场平均增长率 23.6%。尽管预计收入将以每年 18% 的速度强劲增长，但投资者在考虑长期现金流可持续性时应注意不稳定的股息记录。</p>
<ul>
<li>我们编制的增长报告表明，中粮糖业控股有限公司的未来前景可能向好。</li>
<li>在这里深入了解中粮糖业控股有限公司的详细财务健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:600737 截至 2025 年 8 月的折现现金流</p>
<h2>广东丸美生物科技 (SHSE:603983)</h2>
<p><strong>概述：</strong> 广东丸美生物科技有限公司专注于中国的化妆品研究、设计、生产、销售和服务，市值为 CN¥163.3 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其个人产品部门，该部门产生了 CN¥31.6 亿的收入。</p>
<p><strong>公允价值折扣估计：</strong> 48.7%</p>
<p>广东丸美生物科技的交易价格为 CN¥40.73，显著低于其估计的公允价值 CN¥79.37，突显出基于折现现金流分析的潜在低估。预计该公司的收益将以每年 23.7% 的速度增长，略微超过中国市场的平均增长率。预计收入将以每年 21.5% 的速度增长，超出市场预期；然而，1.84% 的股息收益率缺乏自由现金流的覆盖，股本回报率保持在 15.2% 的适度水平。</p>
<ul>
<li>我们的广东丸美生物科技增长报告中的分析暗示未来财务表现强劲。</li>
<li>在这里深入了解广东丸美生物科技的完整分析健康报告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:603983 截至 2025 年 8 月的折现现金流</p>
<h2>MeHow Innovative (SZSE:301363)</h2>
<p><strong>概述：</strong> MeHow Innovative Ltd. 是一家在中国及国际上设计、开发、制造和销售精密医疗设备组件和产品的公司，市值为 CN¥113.3 亿。</p>
<p><strong>运营：</strong> 收入部门（以百万 CN¥计）：</p>
<p><strong>公允价值折扣估计：</strong> 32.6%</p>
<p>MeHow Innovative 的交易价格为 CN¥20.03，低于其估计的公允价值 CN¥29.72，表明基于折现现金流分析的低估。预计未来三年收益将以每年 22.87% 的速度增长，尽管略微落后于更广泛的中国市场增长率 23.6%。预计收入将以每年 21.4% 的速度强劲增长，超过市场平均水平 12.6%，尽管预计股本回报率仅为 13.1%。</p>
<ul>
<li>在审查我们最新的增长报告后，MeHow Innovative 的预期财务表现似乎相当乐观。</li>
<li>点击探索我们在 MeHow Innovative 的资产负债表健康报告中的详细发现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:301363 截至 2025 年 8 月的折现现金流</p>
<h2>利用机会</h2>
<ul>
<li>点击此链接访问基于现金流的 282 只被低估的亚洲股票的完整范围。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取有关您股票的新警告信号的提醒。</li>
<li>利用 Simply Wall St 最大化您的投资潜力，这是一款提供全球市场洞察的综合应用，免费提供。</li>
</ul>
<h2>寻找新视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健股息支付者来多样化您的投资组合，以应对潜在的市场动荡。</li>
<li>通过分析师和管理层的乐观前景，推动您的投资组合中显示强劲增长潜力的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

中粮糖业

丸美生物

<p>随着亚洲市场波动，投资者正在寻找被低估的股票。值得注意的包括 SRE Holdings、SILICON2 和南亚科技，预计折扣在 48.7% 到 49.5% 之间。中粮糖业和广东丸美生物也显示出显著的低估，折扣分别为 40.3% 和 48.7%。这两家公司预计将经历强劲的盈利增长，尽管对股息可持续性存在担忧。分析表明，基于现金流评估，这些被低估的股票可能存在投资机会</p>

<p>As Asian markets experience fluctuations amid global economic shifts, investors are increasingly focused on identifying opportunities within the region's diverse landscape. In this environment, stocks that appear undervalued present intriguing possibilities for those looking to capitalize on potential market inefficiencies.</p>
<div class="lb-trans"><p>随着亚洲市场在全球经济变动中经历波动，投资者越来越关注在该地区多样化的市场中识别机会。在这种环境下，似乎被低估的股票为那些希望利用潜在市场低效的人提供了引人注目的可能性。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基于现金流的亚洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>SRE Holdings (TSE:2980)</td>
<td>¥3180.00</td>
<td>¥6197.35</td>
<td>48.7%</td>
</tr>
<tr>
<td>SILICON2 (KOSDAQ:A257720)</td>
<td>₩53700.00</td>
<td>₩105825.30</td>
<td>49.3%</td>
</tr>
<tr>
<td>Nanya Technology (TWSE:2408)</td>
<td>NT$43.95</td>
<td>NT$87.09</td>
<td>49.5%</td>
</tr>
<tr>
<td>Jiangsu Yunyi ElectricLtd (SZSE:300304)</td>
<td>CN¥11.08</td>
<td>CN¥22.02</td>
<td>49.7%</td>
</tr>
<tr>
<td>Heartland Group Holdings (NZSE:HGH)</td>
<td>NZ$0.80</td>
<td>NZ$1.58</td>
<td>49.5%</td>
</tr>
<tr>
<td>Guangdong Marubi Biotechnology (SHSE:603983)</td>
<td>CN¥40.73</td>
<td>CN¥79.37</td>
<td>48.7%</td>
</tr>
<tr>
<td>GEM (SZSE:002340)</td>
<td>CN¥6.54</td>
<td>CN¥13.00</td>
<td>49.7%</td>
</tr>
<tr>
<td>Finger (KOSDAQ:A163730)</td>
<td>₩13480.00</td>
<td>₩26287.84</td>
<td>48.7%</td>
</tr>
<tr>
<td>cottaLTD (TSE:3359)</td>
<td>¥442.00</td>
<td>¥868.15</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$276.50</td>
<td>NT$541.44</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>当前价格</strong></td>
<td><strong>公允价值（估计）</strong></td>
<td><strong>折扣（估计）</strong></td>
</tr>
<tr>
<td>SRE Holdings (TSE:2980)</td>
<td>¥3180.00</td>
<td>¥6197.35</td>
<td>48.7%</td>
</tr>
<tr>
<td>SILICON2 (KOSDAQ:A257720)</td>
<td>₩53700.00</td>
<td>₩105825.30</td>
<td>49.3%</td>
</tr>
<tr>
<td>Nanya Technology (TWSE:2408)</td>
<td>NT$43.95</td>
<td>NT$87.09</td>
<td>49.5%</td>
</tr>
<tr>
<td>江苏云亿电气有限公司 (SZSE:300304)</td>
<td>CN¥11.08</td>
<td>CN¥22.02</td>
<td>49.7%</td>
</tr>
<tr>
<td>Heartland Group Holdings (NZSE:HGH)</td>
<td>NZ$0.80</td>
<td>NZ$1.58</td>
<td>49.5%</td>
</tr>
<tr>
<td>广东丸美生物科技 (SHSE:603983)</td>
<td>CN¥40.73</td>
<td>CN¥79.37</td>
<td>48.7%</td>
</tr>
<tr>
<td>GEM (SZSE:002340)</td>
<td>CN¥6.54</td>
<td>CN¥13.00</td>
<td>49.7%</td>
</tr>
<tr>
<td>Finger (KOSDAQ:A163730)</td>
<td>₩13480.00</td>
<td>₩26287.84</td>
<td>48.7%</td>
</tr>
<tr>
<td>cottaLTD (TSE:3359)</td>
<td>¥442.00</td>
<td>¥868.15</td>
<td>49.1%</td>
</tr>
<tr>
<td>Andes Technology (TWSE:6533)</td>
<td>NT$276.50</td>
<td>NT$541.44</td>
<td>48.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 282 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>点击这里查看我们基于现金流的 282 只被低估的亚洲股票的完整列表。</p>
</div><p>We'll examine a selection from our screener results.</p>
<div class="lb-trans"><p>我们将从我们的筛选结果中审查一些选项。</p>
</div><h2>Cofco Sugar HoldingLTD (SHSE:600737)</h2>
<div class="lb-trans"><h2>中粮糖业控股有限公司 (SHSE:600737)</h2>
</div><p><strong>Overview:</strong> Cofco Sugar Holding Co., Ltd. operates in sugar and tomato processing both in China and internationally, with a market cap of CN¥21.84 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中粮糖业控股有限公司在中国及国际上从事糖和番茄加工，市值为 CN¥218.4 亿。</p>
</div><p><strong>Operations:</strong> Cofco Sugar Holding CO., LTD. generates revenue primarily through its activities in sugar and tomato processing across domestic and international markets.</p>
<div class="lb-trans"><p><strong>运营：</strong> 中粮糖业控股有限公司主要通过其在国内和国际市场的糖和番茄加工活动产生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 40.3%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 40.3%</p>
</div><p>Cofco Sugar Holding LTD is trading at CN¥10.21, significantly below its estimated fair value of CN¥17.11, indicating potential undervaluation based on discounted cash flow analysis. The company's earnings are forecast to grow significantly at 36.89% annually, outpacing the Chinese market's average growth rate of 23.6%. While revenue growth is expected to be robust at 18% per year, investors should note the unstable dividend track record when considering long-term cash flow sustainability.</p>
<div class="lb-trans"><p>中粮糖业控股有限公司的交易价格为 CN¥10.21，显著低于其估计的公允价值 CN¥17.11，表明基于折现现金流分析的潜在低估。预计该公司的收益将以每年 36.89% 的速度显著增长，超过中国市场平均增长率 23.6%。尽管预计收入将以每年 18% 的速度强劲增长，但投资者在考虑长期现金流可持续性时应注意不稳定的股息记录。</p>
</div><ul>
<li>The growth report we've compiled suggests that Cofco Sugar HoldingLTD's future prospects could be on the up.</li>
<li>Dive into the specifics of Cofco Sugar HoldingLTD here with our thorough financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们编制的增长报告表明，中粮糖业控股有限公司的未来前景可能向好。</li>
<li>在这里深入了解中粮糖业控股有限公司的详细财务健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/d93c71ee-149b-4a67-bc29-bddbe7101502/chart/dcf?theme=light"/></p>
<p>SHSE:600737 Discounted Cash Flow as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:600737 截至 2025 年 8 月的折现现金流</p>
</div><h2>Guangdong Marubi Biotechnology (SHSE:603983)</h2>
<div class="lb-trans"><h2>广东丸美生物科技 (SHSE:603983)</h2>
</div><p><strong>Overview:</strong> Guangdong Marubi Biotechnology Co., Ltd. focuses on the research, design, production, sale, and service of cosmetics in China with a market cap of CN¥16.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 广东丸美生物科技有限公司专注于中国的化妆品研究、设计、生产、销售和服务，市值为 CN¥163.3 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Personal Products segment, which generated CN¥3.16 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其个人产品部门，该部门产生了 CN¥31.6 亿的收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48.7%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 48.7%</p>
</div><p>Guangdong Marubi Biotechnology is trading at CN¥40.73, significantly below its estimated fair value of CN¥79.37, highlighting potential undervaluation based on discounted cash flow analysis. The company's earnings are forecast to grow at 23.7% annually, slightly outpacing the Chinese market's average growth rate. Revenue is expected to increase by 21.5% per year, surpassing market expectations; however, the dividend yield of 1.84% lacks coverage from free cash flows and return on equity remains modest at 15.2%.</p>
<div class="lb-trans"><p>广东丸美生物科技的交易价格为 CN¥40.73，显著低于其估计的公允价值 CN¥79.37，突显出基于折现现金流分析的潜在低估。预计该公司的收益将以每年 23.7% 的速度增长，略微超过中国市场的平均增长率。预计收入将以每年 21.5% 的速度增长，超出市场预期；然而，1.84% 的股息收益率缺乏自由现金流的覆盖，股本回报率保持在 15.2% 的适度水平。</p>
</div><ul>
<li>The analysis detailed in our Guangdong Marubi Biotechnology growth report hints at robust future financial performance.</li>
<li>Delve into the full analysis health report here for a deeper understanding of Guangdong Marubi Biotechnology.</li>
</ul>
<div class="lb-trans"><ul>
<li>我们的广东丸美生物科技增长报告中的分析暗示未来财务表现强劲。</li>
<li>在这里深入了解广东丸美生物科技的完整分析健康报告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/a3fdc12f-9db8-445d-80e6-9b615dd8952d/chart/dcf?theme=light"/></p>
<p>SHSE:603983 Discounted Cash Flow as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:603983 截至 2025 年 8 月的折现现金流</p>
</div><h2>MeHow Innovative (SZSE:301363)</h2>
<div class="lb-trans"><h2>MeHow Innovative (SZSE:301363)</h2>
</div><p><strong>Overview:</strong> MeHow Innovative Ltd. is a company that designs, develops, manufactures, and sells precision medical device components and products in China and internationally, with a market cap of CN¥11.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MeHow Innovative Ltd. 是一家在中国及国际上设计、开发、制造和销售精密医疗设备组件和产品的公司，市值为 CN¥113.3 亿。</p>
</div><p><strong>Operations:</strong> Revenue Segments (in millions of CN¥):</p>
<div class="lb-trans"><p><strong>运营：</strong> 收入部门（以百万 CN¥计）：</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 32.6%</p>
<div class="lb-trans"><p><strong>公允价值折扣估计：</strong> 32.6%</p>
</div><p>MeHow Innovative is trading at CN¥20.03, below its estimated fair value of CN¥29.72, suggesting undervaluation based on discounted cash flow analysis. Earnings are projected to grow 22.87% annually over the next three years, although slightly lagging behind the broader Chinese market growth rate of 23.6%. Revenue growth is expected to be robust at 21.4% per year, outpacing the market average of 12.6%, despite a forecasted return on equity of only 13.1%.</p>
<div class="lb-trans"><p>MeHow Innovative 的交易价格为 CN¥20.03，低于其估计的公允价值 CN¥29.72，表明基于折现现金流分析的低估。预计未来三年收益将以每年 22.87% 的速度增长，尽管略微落后于更广泛的中国市场增长率 23.6%。预计收入将以每年 21.4% 的速度强劲增长，超过市场平均水平 12.6%，尽管预计股本回报率仅为 13.1%。</p>
</div><ul>
<li>Upon reviewing our latest growth report, MeHow Innovative's projected financial performance appears quite optimistic.</li>
<li>Click to explore a detailed breakdown of our findings in MeHow Innovative's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在审查我们最新的增长报告后，MeHow Innovative 的预期财务表现似乎相当乐观。</li>
<li>点击探索我们在 MeHow Innovative 的资产负债表健康报告中的详细发现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/52088d4a-b234-4222-b5fb-5f505cb6f054/chart/dcf?theme=light"/></p>
<p>SZSE:301363 Discounted Cash Flow as at Aug 2025</p>
<div class="lb-trans"><p>SZSE:301363 截至 2025 年 8 月的折现现金流</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Access the full spectrum of 282 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接访问基于现金流的 282 只被低估的亚洲股票的完整范围。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取有关您股票的新警告信号的提醒。</li>
<li>利用 Simply Wall St 最大化您的投资潜力，这是一款提供全球市场洞察的综合应用，免费提供。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>通过提供可靠收入来源的稳健股息支付者来多样化您的投资组合，以应对潜在的市场动荡。</li>
<li>通过分析师和管理层的乐观前景，推动您的投资组合中显示强劲增长潜力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。</strong> 我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

3 只亚洲股票预计以高达 48.7% 的折扣进行交易